"In addition, the license option agreement includesa) an option to negotiate a licence for manufacturing CYP-001 product andb) certain rights to Cynata’s proprietary Cymerus technology for the prevention and treatment ofother diseases.Exercise of the rights to these additional components attracts further fees."
I bet Fuji has a comprehensive balance sheet that tells it what the tipping point is for making a t/o rather than than making ongoing payments under different licencing scenarios. Unfortunately, only they know what these different scenarios are.
Did I read somewhere that of 800+ potential diseases CYP had identified 100+ for which its technology could be a solution?
That is a LOT of fees & royalties!
Going forward..., page-1196
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $34.32M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27580 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 44000 | 1 |
View Market Depth
| Last trade - 10.02am 02/12/2024 (20 minute delay) ? |
| CYP (ASX) Chart |
Day chart unavailable
